Latest News

High-voltage power lines carry electricity generated by the Tennessee Valley Authority to ORNL. Credit: Dobie Gillispie/ORNL, U.S. Dept. of Energy
News

ORNL, TVA partner to drive decarbonization, explore carbon-free technologies

ORNL, TVA partner to drive decarbonization, explore carbon-free technologies

dunlapkk@ornl.gov Mon, 02/28/2022 - 11:25

ORNL and the Tennessee Valley Authority, or TVA, are joining forces to advance decarbonization technologies from discovery through deployment through a new memorandum of understanding, or MOU.

Credit: Unsplash
News

Co-occurring droughts could threaten global food security

Co-occurring droughts could threaten global food security

rosenthalec@ornl.gov Fri, 02/25/2022 - 15:50

Droughts occurring at the same time across different regions of the planet could place an unprecedented strain on the global agricultural system and threaten the water security of millions of people, according to a new study in Nature Climate Change. 

Materials Engineering and Testing Corporation and Schmiede Corporation were among the companies honored at the 2021 ORNL Small Business Awards. Both firms provide critical components and services for the High Flux Isotope Reactor, a DOE Office of Science user facility, pictured above. Credit: Carlos Jones/ORNL, U.S. Dept. of Energy
News

ORNL honors exceptional small business partners

ORNL honors exceptional small business partners

dunlapkk@ornl.gov Thu, 02/24/2022 - 09:35

Four small businesses and one employee were recognized for their exceptional performance in support of ORNL at the 2021 Small Business Awards ceremony held virtually on Wednesday. The annual event honors small businesses that have made a positive impact on ORNL’s operations.

<p>Infection of the lungs by pathogens like SARS-CoV-2 causes inflammation, which can turn deadly. Azeliragon reduces inflammation by blocking the activity of a protein called RAGE, and could be used to treat multiple lung diseases, including COVID-19. Credit: Shutterstock</p>
News

Cantex licenses intellectual property from Harvard University to develop repurposed drug identified by Wyss Institute to treat inflammatory lung diseases including COVID-19

By Lindsay Brownell (BOSTON, MA and WESTON, FL) – Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company based in Weston, FL, and the Wyss Institute for Biologically Inspired Engineering at Harvard University announced today that Cantex has secured a global license from Harvard University’s Office of Technology Development (OTD) to develop azeliragon, a small-molecule drug in clinical…